New GABA-targeting therapies for the treatment of seizures and epilepsy: II. Treatments in clinical development. CNS Drugs 37, 781–795 (2023). Article CAS PubMed PubMed Central Google Scholar Cerne, R. et al. GABAkines — advances in the discovery, development, and commercialization of ...
New epilepsy treatments There are also different treatments being developed for epilepsy. These include new medications and surgical procedures. A 2023 clinical trial found that, when added to current treatments, a new drug called XEN1101 was associated with reduced seizures in people with focal seizu...
In January 2023 - Zydus Lifesciences established Topiramate extended-release capsules, a generic medication for treating epilepsy in the United States market. In March 2022 - Lupin's abbreviated new Vigabatrin application (ANDA), an antiepileptic drug available as an oral solution USP (500 mg), re...
UCL researchers find that slow brain waves, common in sleep, also occur in awake epilepsy patients, protecting against seizures but affecting memory, hinting at new epilepsy treatments. Slow waves that usually only occur in the brain during sleep are also present during wakefulness in people with ...
Epilepsy is a highly heritable disorder affecting over 50 million people worldwide, of which about one-third are resistant to current treatments. Here we report a multi-ancestry genome-wide association study including 29,944 cases, stratified into thr
Despite the approval of similar to 20 additional antiseizure medications (ASMs) since the 1980s, one-third of epilepsy patients experience seizures despite therapy. Drug-resistant epilepsy (DRE) is associated with cognitive and psychiatric comorbidities, socioeconomic impairment, injuries, and a 9.3-...
Special Issue on Dietary treatments for epilepsy & neurological disorders Edited byDr. J. Helen Cross,Dr. Eric H. Kossoff Last update July 2012 Special Issue on Epilepsy Research UK Workshop 2010 on ``Preictal Phenomena'' Edited byProf Markn Richardson,Prof John Jefferys ...
Our mission: to improve the lives of people with epilepsy by promoting awareness, providing support, advancing research towards better treatments, and to ensure that all individuals with epilepsy have access to quality care and resources
Crick, said, "At the moment, there's a clear need for drugs that specifically target the biological nature of CDD. We've made a molecular link between CDKL5 and Cav2.3, mutations which produce similar disorders. Inhibiting Cav2.3 could be a route for trials of future targeted treatments."...
Due to its complex and multifaceted nature, developing effective treatments for epilepsy is still a major challenge. To deal with this complexity we introduce the concept of degeneracy to the field of epilepsy research: the ability of disparate elements